Revenue

Rigetti Computing posts a $52.6M quarterly loss but secures major partnerships and potential government funding, betting big on its long-term quantum strategy.

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

Clipper Realty's latest earnings reveal a stark divide. Record-breaking residential rents are being overshadowed by a major commercial property default.

The iconic Canadian jeweler is delisting from the NYSE American. We dig into the financial pressures and strategic calculus behind this pivotal move.

Ad-tech firm Sabio Holdings secures a $1.5M loan at a staggering 25% interest. Is this a shrewd move to fuel growth or a sign of pressure in a tough market?

Beyond record revenues, Russel Metals' latest report shows a masterclass in strategy. A key acquisition is paying off big, and its performance is a bellwether for a resurgent U.S. industrial economy.

Amid looming US tariffs, PacifiCan is set to unveil new investments. Is this a short-term fix or a long-term strategy for BC's economic future?

Despite a net loss, Drilling Tools International's Q2 results show surprising strength, driven by innovative tech and robust free cash flow.

The luxury resale giant posted a record quarter and raised its 2026 forecast, but a wider GAAP loss tells a more complex story of strategic growth.

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

Genpact's stellar Q2 results are more than just numbers; they're proof of a strategic pivot to 'Agentic Operations' that could reshape the BPO landscape.

Cryoport hits a key profitability milestone, but the real story is its tightening grip on the booming gene therapy market. Is this a true turning point?

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

After Commerce.com's dismal Q2 results and stock plunge, AI-native rival Rezolve Ai declares its rejected merger proposal was the right path all along.

A startup led by ex-Novo Nordisk execs plans a reverse takeover to fund its made-in-Canada generic Ozempic, aiming to disrupt a C$3.5B market.

Beyond a top global ranking, BC Place is leveraging record event growth to drive hundreds of millions in economic impact and redefine Vancouver's world stage.